BoFA Notes BridgeBio Pharma, Inc. (BBIO)'s Upcoming Q4 Earnings May Have Limited Market Impact

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is given twelfth position on our list of best healthcare stocks.

TheFly reported on February 3 that Bank of America analyst Jason Zemansky raised its price target on BBIO to $88 from $85 and maintained a Buy rating on the shares. The firm noted that, given the level of pre-announcements, the company’s upcoming Q4 earnings may not have the same market impact as in previous years, which reflects tempered investor expectations ahead of the report.

Separately, earlier on January 27, Barclays initiated coverage of BridgeBio Pharma, Inc. (NASDAQ:BBIO) with an Overweight rating and a $157 price target. According to the firm, the biotech industry is well-positioned for growth, and many companies are still undervalued, so it has a bright future in 2026. Expectations for more mergers and acquisitions, solid underlying fundamentals, and less attention to medication prices are all anticipated to be significant tailwinds for businesses operating in the sector, according to Barclays.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a U.S. biopharmaceutical company innovating genetic medicine by discovering and developing transformative therapies that target the root causes of rare genetic diseases and cancers, advancing breakthrough gene and precision therapies from early research through clinical and commercial stages.

While we acknowledge the potential of BBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.